Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...89101112131415161718...3132»
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Sputnik V (Twitter) -  Jul 9, 2021   
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    New P2/3 trial:  OLSTAD: Study of Gam-COVID-Vac in Adolescents (clinicaltrials.gov) -  Jul 8, 2021   
    P2/3,  N=350, Not yet recruiting, 
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    @EMA_News and sputnikv? (Twitter) -  Jul 4, 2021   
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    Trial completion date, Trial initiation date, Trial primary completion date:  Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 (clinicaltrials.gov) -  Jul 2, 2021   
    P1/2,  N=100, Not yet recruiting, 
    Trial completion date: Oct 2021 --> Apr 2022 | Initiation date: Mar 2021 --> Aug 2021 | Trial primary completion date: Oct 2021 --> Apr 2022
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Adenovirus and RNA-based COVID-19 vaccines' perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey. (Pubmed Central) -  Jun 30, 2021   
    Awareness by HCWs of the several COVID-19 candidate vaccines could improve their perceptions and acceptance of vaccination. Reliable sources on vaccine efficiency could improve vaccine uptake, so healthcare authorities should use reliable information to decrease vaccine hesitancy among frontline healthcare providers.